Form 8-K - Current report:
SEC Accession No. 0001193125-25-006197
Filing Date
2025-01-14
Accepted
2025-01-14 16:36:23
Documents
13
Period of Report
2025-01-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d875953d8k.htm   iXBRL 8-K 24646
  Complete submission text file 0001193125-25-006197.txt   147000

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kura-20250113.xsd EX-101.SCH 2865
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kura-20250113_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kura-20250113_pre.xml EX-101.PRE 11271
15 EXTRACTED XBRL INSTANCE DOCUMENT d875953d8k_htm.xml XML 3639
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 25529781
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)